1 Introduction
Extramammary Paget’s disease (EMPD) is a rare malignant intraepidermal adenocarcinoma that mainly affects the regions rich in apocrine glands, such as the external genitalia, perianal, inguinal, and axilla (1). Globally, the incidence of EMPD was estimated at 0.1–2.4/106/year (2). Specifically, the prevalence is four times higher in the Asian population than in the worldwide (2). EMPD seems to show obvious racial differences, as it is common in menopausal women in Caucasians, while the incidence is significantly higher in males in China, with a male-to-female ratio of about 8:1 (3). In the early stage of EMPD, the skin lesions have no distinct specificity and are easily confused with non-tumor skin diseases such as eczema and jock itch, and the misdiagnosis rate is high. In 2015, a retrospective study of 246 Chinese male patients with EMPD found that almost all patients were not diagnosed in time, and the average time to diagnosis was 43.2 months after the appearance of the skin lesion (4). Early diagnosis is imperative because the diagnosis is frequently delayed and there is a high incidence of related invasive disorders.
Surgical resection is still the preferred approach for EMPD treatment. However, due to the unclear tumor boundary and affected mucosal regions (e.g., anorectal, urethra, vagina), EMPD is hard to be resected completely. Thus, most EMPD patients experience recurrence 2–3 years after surgery, and the recurrence rate is almost 60% (1). Additionally, those patients with special and huge skin lesions after surgery require skin transplantation and tissue reconstruction, often suffer postoperative appearance and structure function. Furthermore, approximately 20% of EMPD are invasive (5), the incidence of proximal lymph node and distant metastases in invasive EMPD ranges from 34%–61%, and the 5-year survival rate after distant metastases is only 7% (6, 7).
These difficulties mentioned above are caused by the unclear pathogenesis of EMPD. Therefore, uncovering the pathogenesis of EMPD will facilitate the identification of effective therapeutic interventions to repress or eliminate it in the early stage. Most studies mainly focused on evaluating the clinicopathological characteristics of EMPD by immunohistochemical (IHC) staining, and the pathogenesis has not been revealed (8, 9). With the sequencing technology development, more and more researchers employed whole-exome sequencing (WES) and gene expression array or RNA-sequencing approaches to dissect the mechanism of EMPD. Several genes, such as KMT2C (10) with high mutation, FOXA1 (11), and NEAT1 (12) were revealed as potential oncogenic genes for EMPD. However, there is little knowledge about the distortion of metabolism in EMPD. Metabolomics is a new omics after genomics, transcriptomics, and proteomics, which represents all of the low-molecular metabolites and it is an important reflection of various disorders (13). Thus, the metabolic signature of EMPD needs to be investigated.
In the present study, we aim to explore the metabolome of EMPD and identify the metabolic marker of EMPD, which will facilitate the illumination of the pathogenesis of EMPD and the diagnosis and treatment of EMPD from the perspective of metabolomics.
2 Materials and methods
2.1 Sample collection and preparation
This study was reviewed and approved by the Medical Ethics Committee of Shanghai Skin Disease Hospital, and all participants provided were consented preoperatively to enroll in this study with the understanding that it might be published. All samples were used according to the ethical standards. A total of six EMPD patients were enrolled in this study, and all diagnoses of EMPD were verified by hematoxylin and eosin (HE) staining and IHC staining before the definitive surgical procedure according to our previous staining protocol (14). All the IHC staining antibodies were purchased from Mai Xin Biotechnology Development Co., Ltd., including pan cytokeratin (CK, MAB-0050), CK7 (MAB-0828), carcinoembryonic antigen (CEA, MAB-0852), and epithelial membrane antigen (EMA, Kit-0011). Additionally, patient-matched normal adjacent skin tissue was taken from the area around the EMPD lesion, which was determined by two clinicians to be normal skin, and part of the tissue was subjected to HE staining to confirm that it was normal tissue. All these six patients were males with ages ranging from 62 to 82 (71.5 ± 7.92) years old. Then, the EMPD tumor sample and patient-matched normal adjacent skin sample were collected during surgical resection and immediately quickly frozen in liquid nitrogen and stored at −80°C refrigerator for following metabolic experiment.
Then, a total of 100 mg of each sample was grounded in liquid nitrogen and the homogenate was transferred into the EP tube with 500 μL prechilled 80% methanol to resuspend by well vortex. The samples were placed on ice for 5 min and then were centrifuged at 15,000g for 20 min at 4°C. Then, supernatant for each sample was diluted by the liquid chromatography-mass spectrometry (LC-MS) grade water to final concentration containing 53% methanol. Subsequently, the samples were transferred to a new tube and then were centrifuged at 15,000g for 20 min at 4°C. To generate the quality control (QC) sample, 20 mL of supernatant from each sample was mixed into a QC sample. Finally, the supernatant of each sample was injected into the liquid chromatography tandem-mass spectrometry (LC-MS/MS) system (15).
2.2 Untargeted metabolome experiment
Ultra high performance liquid chromatography tandem-mass spectrometry (UHPLC-MS/MS) analysis was performed on the Vanquish UHPLC system (Thermo Fisher Scientific, Massachusetts, USA) coupled with an Orbitrap Q Exactive™ HF mass spectrometer (Thermo Fisher Scientific, Massachusetts, USA). In detail, chromatographic separation was conducted in Vanquish UHPLC system equipped with a Hypersil GOLD columns (100 mm × 2.1 mm, 1.9 μm) using a 17-min linear gradient at a flow rate of 0.2 mL/min. The eluents for the positive polarity mode were eluent A (0.1% FA in water) and eluent B (methanol). The eluents for the negative polarity mode were eluent A (5 mM ammonium acetate, pH 9.0) and eluent B (methanol). The solvent linear gradient was set as follows: 2% B, 1.5 min; 2%−100% B, 12.0 min; 100% B, 14.0 min; 100%−2% B, 14.1 min; 2% B, 17 min. The ESI-MSn experiments were executed on a Q ExactiveTM HF mass spectrometer in positive/negative polarity mode with spray voltage of 3.2 kV. Sheath gas and auxiliary gas flow e were set at 40 and 10 arbitrary units, respectively, and the capillary temperature was 320°C. The analyzer scanned over a mass range of 100 m/z–15,000 m/z for full scan at a mass resolution of 70,000. Finally, data-dependent acquisition MS/MS experiments were performed.
2.3 Data preprocessing and metabolite identification
The raw data generated by UHPLC-MS/MS platform was processed using the Compound Discoverer software (v3.1, Thermo Fisher Scientific, Massachusetts, USA) to perform peak alignment, peak picking, and quantitation. The main parameters were set as follows: 0.2 min for retention time tolerance, 5 ppm for actual mass tolerance, 30% for signal intensity tolerance, 3 for signal/noise ratio, and minimum intensity. After that, peak intensities were normalized to the total spectral intensity. Then, the normalized data were used to predict the molecular formula based on additive ions, molecular ion peaks, and fragment ions, which were further matched with the mzCloud, mzVault, and MassList database to obtain the accurate qualitative and relative quantitative results of metabolites.
2.4 Bioinformatics analyses
All metabolites were annotated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database, HMDB database, and LIPIDMaps database. Data normalization, principal components analysis (PCA), partial least squares discriminant analysis (PLS-DA), random forest (RF) and support vector machine (SVM) were performed using MetaboAnalystR R-package (16). Univariate analysis (t-test) was used to calculate the differential metabolites. Any metabolites with the value of value importance in projection (VIP) > 1, P < 0.05 and | log2 (fold change) | > 1 were considered to be differential metabolites. To view the metabolites content, the metabolites data were normalized as z-scores and visualized by pheatmap R-package. The differential metabolites were used to conduct an over-representation analysis enrichment analysis, and enriched KEGG pathways with P < 0.05 were considered as statistically significant.
2.5 Gene expression microarray analysis
To link the potential relationship between metabolome and transcriptome in EMPD, we described the gene expression profile of EMPD using a public microarray dataset with the accession code of GSE117285 from the Gene Expression Omnibus database (17). Specifically, gene expressions of eight samples, including four normal skins and four EMPD patients, were obtained from Agilent-039494 Sure-Print G3 Human GE v2 8 × 60K microarray. After QC, differentially expressed genes (DEGs) identification was conducted using limma R-package with log2 transformed expression signal matrix. P-value was adjusted by false discovery rate. Gene with | log2 (fold change) | > 1 and an adjusted P < 0.05 was considered as a differential expression.
Then, the DEGs were used for Gene Ontology (GO) functional annotation, regarding biological process (BP), cellular component (CC), and molecular function (MF) using clusterProfiler R-package (18). A term with P < 0.05 was considered statistically significant. Gene set enrichment analysis (GSEA) was conducted based on the results of the DEG analysis using the clusterProfiler R-package, and C2-curated gene sets of KEGG pathway for human (v7.2) was downloaded from MSigDB (19). The gene list was ranked according to the log2 (fold change) and used as an input for the GSEA. P-value was adjusted by Benjamini and Hochberg method and adjusted P < 0.05 was considered as statistically significant. All the results were visualized in R software with different packages.
2.6 Metabolite content validation
In order to validate the metabolome result, we employed another independent HPLC-MS instrument to validate the differential metabolite in EMPD and normal skin samples, which was performed by Wuhan Servicebio Technology Co., LTD according to a standard protocol. Briefly, 100 μL of each sample was prepared, then added into 900 μL of methanol, and centrifuged at 13,000 rpm for 10 min at 4°C. The supernatant was collected for HPLC-MS analysis with using Thermo TSQ Quantum (Thermo Fisher Scientific, Germany) and Thermo UltiMate 3000 RS (Thermo Fisher Scientific, Germany). Finally, data were analyzed by Xcalibur (Thermo Fisher Scientific, Germany).
3 Results
3.1 Morphological characteristics of EMPD
All EMPD patients were confirmed by HE and IHC before surgery. The key pathological characteristic was the presence of Paget’s cells in the epidermis (Figure 1). Paget’s cells exhibited a clear staining with abundant cytoplasm and large nuclei and are often associated with mitosis. IHC staining showed high expression of CEA, EMA, and CK7 in Paget’s cells. Malignant cells sometimes infiltrated the hair follicles and sweat gland ducts.
3.2 Metabolome of EMPD
To clarify the profile of local lipid metabolism in EMPDs, we used non-targeted metabolome analysis to detect metabolites. A total of 896 metabolites were identified. PCA showed that a larger heterogeneity was found in the control group than in the EMPD group, as the samples from EMPD group gathered very well (Figure 2A). Then, we described the metabolic profile using a stacked histogram with calculating the percentage of each metabolite in each individual. The top 20 metabolites including Palmitic acid, Elaidic acid, Arachidonic acid, Stearic acid, 16-Hydroxyhexadecanoic acid, L-Phenylallaine, Lauric acid ethyl ester, 8Z,11Z,14Z-Eicosatrienoic acid, Indole-3-acrylic acid, DL-tryptophan, and so on (Figure 2B). The metabolites except the top 20 were grouped into the other class. Similarly, the grouped percentage of each metabolite for these two groups was also showed (Figure 2B). The heatmap showed the top 30 metabolites across different samples (Figure 2C). Generally, there was no significant difference for the major metabolites between the control and the EMPD group.
3.3 Differential metabolites in EMPD by univariate analysis
The PLS-DA model was used to calculate the importance of each metabolite defined by VIP value (Figure 3A). In general, the VIP value of a differential metabolite should > 1. Univariate analysis was used to detect the differential metabolites between these two groups. We quantified the change of each metabolite by calculating the fold change (FC) of the normalized metabolite content and identified the significance with the P-value by t-test. A total of 87 metabolites including 37 upregulated and 50 downregulated significantly in EMPD were identified (Figure 3B), which should be studied in the further research. Specifically, feruloyl putrescine was the most significantly upregulated metabolite in EMPD (FC = 4.52, VIP = 2.32), followed by 6-Methylnicotinamide (FC = 3.41, VIP = 2.29), and O-Phosphorylethanolamine (FC = 2.02, VIP = 2.28). Regarding the downregulated metabolites, lipopolysaccharide (LPS) 18:2 was the most downregulated one (FC = 0.38, VIP = 2.34), followed by Guanosine-3’,5’-cyclic monophosphate (FC = 0.07, VIP = 2.54), and Cyclopentyl fentanyl-d5 (FC = 0.14, VIP = 2.39). To visually show the contents of 87 differential metabolites among these 12 samples, unsupervised cluster method and heatmap were used. Two distinct clusters in each group were spited automatically, representing downregulated and upregulated metabolites, respectively (Figure 3C).
3.4 Feature selection in EMPD by machine learning
To further identified the EMPD-specific features, machine learning methods including RF and SVM were used. The most 15 important metabolites for distinguish EMPD from the control were identified by these two methods (Figures 4A, B). For RF analysis, the most 15 important metabolites were Cyclopentyl fentanyl-d5, LPI 17:0, Guanosine-3’,5’-cyclic monophosphate, LPC 12:0, O-Phosphorylethanolamine, Kynurenine (KYN), 3’-Adenosine monophosphate, 4-Toluenesulfonic acid, N-Acetylaspartic acid, Adenylosuccinic acid, LPC 16:2, 11β-Prostaglandin E2, Ala-trp, and PG (18:2/20:3) (Figure 4A). In the SVM analysis, the most 15 important metabolites were Cyclopentyl fentanyl-d5, LPS 18:2, Guanosine-3’,5’-cyclic monophosphate, FAHFA (18:2/17:0), Feruloyl Putrescine, 1-adamantyl (piperidino) methanone, Cuminaldehyde, Prostaglandin F2α 1-11-lactone, LPI 17:0, Adenosine, KYN, 10-Nitrolinoleate, N’-(benzoyloxy)-2-(2,2-dichlorocyclopropyl) ethanimidamide, LPG 15:0, and 2,4-Dimethylbenzaldehyde (Figure 4B). However, only four of 15 metabolites were shared by RF and SVM analyses, including Cyclopentyl fentanyl-d5 (high in control), LPI 17:0 (high in control), Guanosine-3’,5’-cyclic monophosphate (high in control), KYN (high in EMPD). All of these four metabolites were differential between EMPD and the control group.
3.5 Metabolic pathway enrichment analysis
As lots of differential metabolites were identified between EMPD and the control group, KEGG enrichment analysis was performed to explore the potential biological pathways that may play a crucial role in the pathogenesis of EMPD. A total of five significant pathways were enriched including alanine, aspartate and glutamate metabolism, purine metabolism, beta-alanine metabolism, histidine metabolism, and pantothenate and CoA biosynthesis (Figure 4C). Topological analysis can assess the impact of the metabolite in the significantly enriched metabolic pathway. Therefore, we combined this analysis to determine whether a metabolic pathway plays a key role in the progression of EMPD. Similarly, alanine, aspartate, and glutamate metabolism were determined as the most impact pathway in the current study (Figure 4D).
To further validate the differential metabolite, we used another independent HPLC-MS instrument to validate the differential metabolite in EMPD and normal skin samples. As shown in Figure 5, the KYN content was significantly enriched in EMPD (P < 0.05).
3.6 Changed gene expression profile of EMPD
In order to further investigate the potential relationship between metabolites and gene expression, we re-analyzed the gene expression microarray data (GSE117285), which containing four EMPD patients and four normal skins. The PCA result showed that these two groups were clustered very well, indicating a distinct difference between EMPD and normal skin at the transcriptomic level (Figure 6A). A total of 1,079 DEGs including 646 upregulated and 433 downregulated in the EMPD patients (Figure 6B). All the 1,079 DEGs were presented by gene expression heatmap (Figure 6C). Specifically, five chemokines or their receptors including CXCL1, CXCL2, CXCL9, CXCL13, and CXCR6 were significantly upregulated in EMPD. In addition, the tryptophan-degrading enzyme including indoleamine-2,3-dioxygenase-1 (IDO1) and tryptophan 2,3-dioxygenase (TDO2) were also increased (Figure 6D). Interestingly, we also observed an increase of KYN, generated by IDO1 or TDO2 in EMPD.
We further employed gene functional annotation to investigate the dysfunctional pathway in EMPD. The top 10 significantly enriched terms of GO enrichment analysis showed that in the BP level, the DEGs involved in organelle fission, nuclear division, keratinocyte differentiation, mitotic nuclear division, and so on (Figure 6E). Regarding the CC level, the DEGs were enriched in chromosome region (Figure 6E). In terms of the MF level, the DEGs were mainly concentrated in the catalytic activity, DNA-dependent ATPase activity, and DNA helicase activity (Figure 6E). Furthermore, we identified a series of KEGG pathway that activated or inhibited in EMPD by the GSEA. Specifically, a total of 21 pathways were activated in EMPD, including cell cycle, spliceosome, TLR signaling pathway, P53 signaling pathway, RNA degradation, basal transcription factors, DNA replication, and mismatch repair (Figure 6F). Meanwhile, eight pathways including glycerolipid metabolism, PPAR signaling pathway, adipocytokine signaling pathway, melanogenesis, calcium signaling pathway, focal adhesion, neuroactive ligand receptor interaction, and basal cell carcinoma were inhibited in EMPD (Figure 6F). However, although the tryptophan metabolic pathway was not significantly identified by GSEA, this pathway showed an activated trend with a positive enrichment score (0.38, adjusted P = 0.44). Collectively, both metabolomic and transcriptomic results indicate that tryptophan metabolic pathway may involve in the development of EMPD.
4 Discussion
EMPD is considered a rare malignant cutaneous carcinoma with poorly outcomes characterized with high recurrence rate. Clinically, pruritic erythematous plaque on local skin is the more frequent initial clinical presentation of EMPD (20), which needs to be differentiated from other chronic dermatitis. The diagnosis of EMPD is frequently delayed, causing older age of patients at diagnosis, which results in decreased survival (5). Thus, a series of studies focused on the dissection of EMPD pathogenesis of EMPD and biomarkers identification such as neutrophil-to-lymphocyte ratio (21). Metabolomics is becoming a powerful omics tool, which has been successfully applied to various cutaneous carcinoma including melanoma (22), cutaneous squamous cell carcinoma (23), and basal cell carcinoma (24). In the present study, we investigated the metabolic signature in EMPD by untargeted metabolomics. Although the major metabolites were not significant difference between EMPD and the paired normal skin, a total of 87 differential metabolites were still identified, which may contribute to the progression of EMPD.
In the present study, we found KYN was significantly elevated in the EMPD, and its importance was confirmed by RF and SM analyses, indicating that KYN may exert crucial role in the EMPD progression. KYN is the carboxylated product derived from the oxidative cleavage of the essential amino acid tryptophan (TRY) (25). Furthermore, The KYN pathway, initiated by indole-amine-2,3-dioxygenase 1/2 (IDO1/2) or tryptophan-2,3-dioxgenase (TDO2), has been considered as the leading TRY catabolic route in humans (26). Interestingly, we also observed the elevated expression of IDO1and TDO2 by re-analyzed the public gene expression data (GSE117285). Accumulated evidences have reported that the activated KYN pathway has been positively correlated with the bad prognosis of different kinds of tumors including colorectal cancer (27), breast cancer (28), and melanoma (29).
KYN is the ligand of aryl hydrocarbon receptor (AHR), which is a transcription factor whose targets regulate various BPs, including angiogenesis, lipid metabolism, cell motility, and immune modulation (30–32). Therefore, cancer trends showed a high expression of IDO1 and/or TDO2 to catabolize TRY, generating abundant KYN that further activates AHR and its targets for the sake of tumor progression (33, 34). The KYN-AHR axis promotes the malignant phenotype of cancer cells, in particular, cancer cell motility (35). Furthermore, KYN-AHR signaling builds an immunosuppressive microenvironment through inducing regulatory T cells differentiation and recruiting immunosuppressive tumor-associated macrophages (36, 37), together with upregulating programmed cell death protein 1 expression in CD8+ T cells and enticing its death (28, 38). Interestingly, there is a study that has reported the action of AHR pathway in EMPD. Sato et al. has proved that the metabolites produced by Malasseziaserve as AHR ligands to activate the AHR pathway and induce the Th17 immune response (39).
Except for the increased expression of IDO1 and TDO2 in EMPD, we also noticed various dysfunctional pathways. More than 20 pathways were activated in EMPD, including cell cycle, basal transcription factors, and DNA replication, indicating that a sustaining proliferative signaling was activated. Furthermore, P53 signaling pathway and mismatch repair pathway were also activated. One WES study showed that TP53 is highly mutated in EMPD, indicating that its tumor suppressor function may be compromised (40), causing tumor cells to escape from apoptosis. Taken together, the increased KYN and IDO1/TDO2 indicate that TRY metabolic pathway initialized by IDO1/TDO2 may exert import role in the progression of EMPD and paired metabolomic and transcriptomic analyses should be performed to confirm our findings in a large EMPD samples.
5 Conclusions
In summary, we explore the metabolome and transcriptome of EMPD in the present study. Both KYN and IDO1/TDO2 were elevated in EMPD, demonstrating that KYN metabolic pathway may play a vital role in the development and progression of EMPD. Our findings provide basic evidence that IDO1/TDO2 may be an important molecule participating in the aberrant activation of TRY metabolic pathway and thus may serve as a potential therapeutic target for treating EMPD.
Data availability statement
The data presented in the study are deposited in the Metabolites repository, accession number MTBLS8797, and the gene expression microarray dataset was downloaded from the Gene Expression Omnibus (GEO) repository, accession number GSE117285.
Ethics statement
The studies involving humans were approved by Medical Ethics Committee of Shanghai Skin Disease Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.
Author contributions
LJ: Data curation, Formal analysis, Methodology, Validation, Writing – original draft. XX: Funding acquisition, Writing – original draft. GY: Formal analysis, Validation, Visualization, Writing – review & editing. YW: Investigation, Writing – review & editing. NX: Investigation, Methodology, Writing – review & editing. YXL: Conceptualization, Project administration, Resources, Supervision, Writing – review & editing. GZ: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing. YQL: Conceptualization, Funding acquisition, Project administration, Resources, Supervision, Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was financially founded by the National Natural Science Foundation of China (82073016 and 82203942), the Shanghai Natural Science Foundation (20ZR1449400, 22ZR1455500 and 23ZR1456100).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. St Claire K, Hoover A, Ashack K, Khachemoune A. Extramammary paget disease. Dermatol Online J (2019) 25:13030/qt7qg8g292. doi: 10.5070/D3254043591
PubMed Abstract | CrossRef Full Text | Google Scholar
2. Simonds RM, Segal RJ, Sharma A. Extramammary paget’s disease: A review of the literature. Int J Dermatol (2019) 58:871–9. doi: 10.1111/ijd.14328
PubMed Abstract | CrossRef Full Text | Google Scholar
3. Herrel LA, Weiss AD, Goodman M, Johnson TV, Osunkoya AO, Delman KA, et al. Extramammary paget’s disease in males: Survival outcomes in 495 patients. Ann Surg Oncol (2015) 22:1625–30. doi: 10.1245/s10434-014-4139-y
PubMed Abstract | CrossRef Full Text | Google Scholar
4. Kang Z, Zhang Q, Zhang Q, Li X, Hu T, Xu X, et al. Clinical and pathological characteristics of extramammary paget’s disease: Report of 246 chinese male patients. Int J Clin Exp Pathol (2015) 8:13233–40.
PubMed Abstract | Google Scholar
5. Weng S, Zhu N, Li D, Chen Y, Tan Y, Chen J, et al. Clinical characteristics, treatment, and prognostic factors of patients with primary extramammary paget’s disease (empd): A retrospective analysis of 44 patients from a single center and an analysis of data from the surveillance, epidemiology, and end results (seer) database. Front Oncol(2020) 10:1114. doi: 10.3389/fonc.2020.01114
PubMed Abstract | CrossRef Full Text | Google Scholar
6. Ohara K, Fujisawa Y, Yoshino K, Kiyohara Y, Kadono T, Murata Y, et al. A proposal for a tnm staging system for extramammary paget disease: Retrospective analysis of 301 patients with invasive primary tumors. J Dermatol Sci (2016) 83:234–9. doi: 10.1016/j.jdermsci.2016.06.004
PubMed Abstract | CrossRef Full Text | Google Scholar
7. van der Linden M, Oonk MHM, van Doorn HC, Bulten J, van Dorst EBL, Fons G, et al. Vulvar paget disease: A national retrospective cohort study. J Am Acad Dermatol(2019) 81:956–62. doi: 10.1016/j.jaad.2018.11.016
PubMed Abstract | CrossRef Full Text | Google Scholar
8. Hata H, Abe R, Hoshina D, Saito N, Homma E, Aoyagi S, et al. Muc5ac expression correlates with invasiveness and progression of extramammary paget’s disease. J Eur Acad Dermatol Venereol (2014) 28:727–32. doi: 10.1111/jdv.12156
PubMed Abstract | CrossRef Full Text | Google Scholar
9. Chang K, Li GX, Kong YY, Shen XX, Qu YY, Jia ZW, et al. Chemokine receptors cxcr4 and cxcr7 are associated with tumor aggressiveness and prognosis in extramammary paget disease. J Cancer (2017) 8:2471–7. doi: 10.7150/jca.19127
PubMed Abstract | CrossRef Full Text | Google Scholar
10. Zhang G, Zhou S, Zhong W, Hong L, Wang Y, Lu S, et al. Whole-exome sequencing reveals frequent mutations in chromatin remodeling genes in mammary and extramammary paget’s diseases. J Invest Dermatol (2019) 139:789–95. doi: 10.1016/j.jid.2018.08.030
PubMed Abstract | CrossRef Full Text | Google Scholar
11. Mai R, Zhou S, Zhou S, Zhong W, Hong L, Wang Y, et al. Transcriptome analyses reveal foxa1 dysregulation in mammary and extramammary paget’s disease. Hum Pathol (2018) 77:152–8. doi: 10.1016/j.humpath.2017.12.030
PubMed Abstract | CrossRef Full Text | Google Scholar
12. Zheng DC, Shen YT, Wei ZW, Wan X, Xie MK, Yao HJ, et al. Transcriptome sequencing reveals a lncrna-mrna interaction network in extramammary paget’s disease. BMC Med Genomics (2021) 14:291. doi: 10.1186/s12920-021-01135-2
PubMed Abstract | CrossRef Full Text | Google Scholar
13. Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol (2019) 20:353–67. doi: 10.1038/s41580-019-0108-4
PubMed Abstract | CrossRef Full Text | Google Scholar
14. Zhang G, Yan G, Fu Z, Wu Y, Wu F, Zheng Z, et al. Loss of retinoic acid receptor-related receptor alpha (roralpha) promotes the progression of uv-induced cscc. Cell Death Dis (2021) 12:247. doi: 10.1038/s41419-021-03525-x
PubMed Abstract | CrossRef Full Text | Google Scholar
15. Want EJ, Masson P, Michopoulos F, Wilson ID, Theodoridis G, Plumb RS, et al. Global metabolic profiling of animal and human tissues via uplc-ms. Nat Protoc (2013) 8:17–32. doi: 10.1038/nprot.2012.135
PubMed Abstract | CrossRef Full Text | Google Scholar
16. Chong J, Xia J. Metaboanalystr: An r package for flexible and reproducible analysis of metabolomics data. Bioinformatics (2018) 34:4313–4. doi: 10.1093/bioinformatics/bty528
PubMed Abstract | CrossRef Full Text | Google Scholar
17. Song Y, Guerrero-Juarez CF, Chen Z, Tang Y, Ma X, Lv C, et al. The msi1-mtor pathway drives the pathogenesis of mammary and extramammary paget’s disease. Cell Res (2020) 30:854–72. doi: 10.1038/s41422-020-0334-5
PubMed Abstract | CrossRef Full Text | Google Scholar
18. Yu G, Wang LG, Han Y, He QY. Clusterprofiler: An r package for comparing biological themes among gene clusters. OMICS (2012) 16:284–7. doi: 10.1089/omi.2011.0118
PubMed Abstract | CrossRef Full Text | Google Scholar
19. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA (2005) 102:15545–50. doi: 10.1073/pnas.0506580102
PubMed Abstract | CrossRef Full Text | Google Scholar
20. Wang Z, Lu M, Dong GQ, Jiang YQ, Lin MS, Cai ZK, et al. Penile and scrotal paget’s disease: 130 chinese patients with long-term follow-up. BJU Int (2008) 102:485–8. doi: 10.1111/j.1464-410X.2008.07575.x
PubMed Abstract | CrossRef Full Text | Google Scholar
21. Maeda T, Uehara J, Toyoshima R, Nakagawa T, Yoshino K. Neutrophil-to-lymphocyte ratio is a potential prognostic biomarker for extramammary paget disease: A retrospective study. J Dermatol (2022) 49:1188–92. doi: 10.1111/1346-8138.16533
PubMed Abstract | CrossRef Full Text | Google Scholar
22. Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature (2020) 585:113–8. doi: 10.1038/s41586-020-2623-z
PubMed Abstract | CrossRef Full Text | Google Scholar
23. Azimi A, Kaufman KL, Ali M, Arthur J, Kossard S, Fernandez-Penas P. Differential proteomic analysis of actinic keratosis, bowen’s disease and cutaneous squamous cell carcinoma by label-free lc-ms/ms. J Dermatol Sci (2018) 91:69–78. doi: 10.1016/j.jdermsci.2018.04.006
PubMed Abstract | CrossRef Full Text | Google Scholar
24. Huang J, Schaefer J, Wang Y, Gioia L, Pei Y, Shi X, et al. Metabolic signature of eyelid basal cell carcinoma. Exp Eye Res (2020) 198:108140. doi: 10.1016/j.exer.2020.108140
PubMed Abstract | CrossRef Full Text | Google Scholar
25. Proietti E, Rossini S, Grohmann U, Mondanelli G. Polyamines and kynurenines at the intersection of immune modulation. Trends Immunol (2020) 41:1037–50. doi: 10.1016/j.it.2020.09.007
PubMed Abstract | CrossRef Full Text | Google Scholar
26. Cervenka I, Agudelo LZ, Ruas JL. Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health. Science (2017) 357:eaaf9794. doi: 10.1126/science.aaf9794
PubMed Abstract | CrossRef Full Text | Google Scholar
27. Santhanam S, Alvarado DM, Ciorba MA. Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer. Transl Res (2016) 167:67–79. doi: 10.1016/j.trsl.2015.07.003
PubMed Abstract | CrossRef Full Text | Google Scholar
28. Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, et al. A role for tryptophan-2,3-dioxygenase in cd8 t-cell suppression and evidence of tryptophan catabolism in breast cancer patient plasma. Mol Cancer Res (2019) 17:131–9. doi: 10.1158/1541-7786.MCR-18-0362
PubMed Abstract | CrossRef Full Text | Google Scholar
29. Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bosse D, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat Commun(2019) 10:4346. doi: 10.1038/s41467-019-12361-9
PubMed Abstract | CrossRef Full Text | Google Scholar
30. Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: Friend and foe. Nat Rev Cancer (2014) 14:801–14. doi: 10.1038/nrc3846
PubMed Abstract | CrossRef Full Text | Google Scholar
31. Gutierrez-Vazquez C, Quintana FJ. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity (2018) 48:19–33. doi: 10.1016/j.immuni.2017.12.012
PubMed Abstract | CrossRef Full Text | Google Scholar
32. Rothhammer V, Quintana FJ. The aryl hydrocarbon receptor: An environmental sensor integrating immune responses in health and disease. Nat Rev Immunol (2019) 19:184–97. doi: 10.1038/s41577-019-0125-8
PubMed Abstract | CrossRef Full Text | Google Scholar
33. Chen JY, Li CF, Kuo CC, Tsai KK, Hou MF, Hung WC. Cancer/stroma interplay via cyclooxygenase-2 and indoleamine 2,3-dioxygenase promotes breast cancer progression. Breast Cancer Res (2014) 16:410. doi: 10.1186/s13058-014-0410-1
PubMed Abstract | CrossRef Full Text | Google Scholar
34. Xiang Z, Li J, Song S, Wang J, Cai W, Hu W, et al. A positive feedback between ido1 metabolite and col12a1 via mapk pathway to promote gastric cancer metastasis. J Exp Clin Cancer Res (2019) 38:314. doi: 10.1186/s13046-019-1318-5
PubMed Abstract | CrossRef Full Text | Google Scholar
35. D’Amato NC, Rogers TJ, Gordon MA, Greene LI, Cochrane DR, Spoelstra NS, et al. A tdo2-ahr signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer. Cancer Res (2015) 75:4651–64. doi: 10.1158/0008-5472.CAN-15-2011
PubMed Abstract | CrossRef Full Text | Google Scholar
36. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory t cells. J Immunol (2010) 185:3190–8. doi: 10.4049/jimmunol.0903670
PubMed Abstract | CrossRef Full Text | Google Scholar
37. Takenaka MC, Gabriely G, Rothhammer V, Mascanfroni ID, Wheeler MA, Chao CC, et al. Control of tumor-associated macrophages and t cells in glioblastoma via ahr and cd39. Nat Neurosci (2019) 22:729–40. doi: 10.1038/s41593-019-0370-y
PubMed Abstract | CrossRef Full Text | Google Scholar
38. Liu Y, Liang X, Dong W, Fang Y, Lv J, Zhang T, et al. Tumor-repopulating cells induce pd-1 expression in cd8(+) t cells by transferring kynurenine and ahr activation. Cancer Cell (2018) 33:480–494 e7. doi: 10.1016/j.ccell.2018.02.005
PubMed Abstract | CrossRef Full Text | Google Scholar
39. Sato Y, Fujimura T, Tanita K, Chunbing L, Matsushita S, Fujisawa Y, et al. Malassezia-derived aryl hydrocarbon receptor ligands enhance the ccl20/th17/soluble cd163 pathogenic axis in extra-mammary paget’s disease. Exp Dermatol (2019) 28:933–9. doi: 10.1111/exd.13944
PubMed Abstract | CrossRef Full Text | Google Scholar
40. Kiniwa Y, Yasuda J, Saito S, Saito R, Motoike IN, Danjoh I, et al. Identification of genetic alterations in extramammary paget disease using whole exome analysis. J Dermatol Sci (2019) 94:229–35. doi: 10.1016/j.jdermsci.2019.03.006
PubMed Abstract | CrossRef Full Text | Google Scholar
Authors: Long Jiang, Xiaoxiang Xu, Guorong Yan, Yuhao Wu, Ningyuan Xi, Yongxian Lai, Guolong Zhang, Yeqiang Liu1 • Frontiers in Oncology, Sec. Cancer Metabolism, Volume 14 - 2024
Frontiers in Oncology • Copyright © 2024 Jiang, Xu, Yan, Wu, Xi, Lai, Zhang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).